Objectives: Polymyxin B is an active agent against many MDR Gram-negative bacteria, but nephrotoxicity is a major hindrance to its widespread use. To guide its optimal use, we determined the risk factors for nephrotoxicity onset associated with polymyxin B.
Introduction
Infections due to MDR Gram-negative bacteria are increasing worldwide.
1,2 Treatment of these infections presents a clinical challenge and multiple studies reported high mortality rates in patients with carbapenem-resistant Enterobacteriaceae, MDR Pseudomonas aeruginosa and MDR Acinetobacter baumannii. 3 -7 Polymyxin B is one of the two polymyxin antibiotics that remain active against these MDR Gram-negative bacteria. However, nephrotoxicity is a major hindrance to widespread clinical use of the polymyxins and historically other alternatives have been preferentially used. Three recent retrospective cohort studies with a large number of patients reported a potentially better nephrotoxicity profile with polymyxin B compared with colistin. 8 -10 In view of these findings and more consistent pharmacological characteristics, the use of polymyxin B is expected to increase in the near future. 11 Identifying ways to minimize nephrotoxicity associated with polymyxin B use is critical to advance clinical practice. Previous studies have evaluated the prevalence rates of nephrotoxicity, described time to the development of acute kidney injury (AKI), examined the impact of different polymyxin B dosing frequencies on the nephrotoxicity and identified independent predictors of AKI. 12 -14 The objective of this study was to investigate the risk factors associated with the onset of nephrotoxicity in patients on polymyxin B therapy. University Langone Medical Center (a 700 bed academic medical centre in New York, NY, USA), New York Hospital Queens (a 520 bed universityaffiliated community hospital in Flushing, NY, USA) and Maimonides Medical Center (a 700 bed tertiary teaching hospital in Brooklyn, NY, USA). Institutional Review Board approvals at each study site and the University of Houston were obtained prior to the initiation of this study. In view of the retrospective nature of the study, the need for informed consent was waived.
Methods

Study design and clinical sites
Patient selection criteria
Adult patients (≥18 years) who were given ≥72 h of intravenous polymyxin B daily for suspected or documented infections were included in this study. Patients with underlying baseline renal insufficiency (baseline serum creatinine .1.5 mg/dL or requiring any form of renal replacement therapy) or fluctuating renal function (increase or decrease in serum creatinine of .50% from baseline 72 h prior to initiation of polymyxin B therapy) were excluded.
Study variables/outcome definition
Data collected included demographics (e.g. age, ethnicity and gender), comorbidities (e.g. diabetes mellitus, cystic fibrosis and ICU stay during polymyxin B therapy), pertinent laboratory findings (e.g. serum creatinine, site of positive culture and organisms isolated), polymyxin B therapy regimens (daily dose prior to the onset of nephrotoxicity and duration) and concomitant nephrotoxins (e.g. aminoglycosides, loop diuretics, vasopressors, calcineurin inhibitors, vancomycin, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers) with polymyxin B therapy. For descriptive purposes, the severity of nephrotoxicity was defined by the RIFLE (risk, injury, failure, loss, end-stage kidney disease) criteria based on the highest serum creatinine observed during polymyxin B therapy and compared with baseline. 15 The primary outcome of the study was the onset of nephrotoxicity regardless of severity (the first day of therapy on which serum creatinine was ≥1.5× the baseline). Patients were followed for up to 30 days from the first day of polymyxin B therapy (considered as baseline) or until hospital discharge, whichever was earlier.
Statistical analysis
To identify independent risk factors associated with the onset of nephrotoxicity, a Cox proportional hazards model was used to analyse the data. Using this analysis framework, we provided an additional time dimension to the outcome of interest, compared with the more conventional (logistic) regression. Right censoring was used for events not directly observed. Univariate analysis was used to derive HRs of different variables. Variables with P values ,0.2 in the univariate analysis were included in a multivariate analysis and backward selection was used. Variables with P values ≤0.05 were considered significant in the final model. To validate the best-fit model, patients were stratified into above versus below the median predicted hazards. Continuous variables were compared using Student's t-test or Kruskal -Wallis one-way analysis of variance. Categorical variables were compared using Fisher's exact test. The time to nephrotoxicity in the stratified cohorts was compared using the Kaplan -Meier survival analysis and log-rank test. All statistical analyses were performed by using SYSTAT version 12 (SYSTAT Software, Chicago, IL, USA).
Results
Baseline characteristics of patients
A total of 192 patients were evaluated. Key demographic and clinical characteristics are summarized in Table 1 . The most common site of positive culture was the respiratory tract (95 patients; 49.5%), followed by urine (51 patients; 26.6%) and the bloodstream (22 patients; 11.5%). The most common bacteria isolated were Klebsiella spp. (92 patients; 47.9%) and A. baumannii (53 patients; 27.6%). The overall prevalence rate of nephrotoxicity was 45.8% (88/192) and the median onset of nephrotoxicity was 9 days (IQR ¼ 5-16 days). Among the 88 patients who developed nephrotoxicity, 3 required haemodialysis. Based on the data recorded on the last day, serum creatinine returned to ,1.5× the baseline in 36 out of 85 (42.4%) non-dialysis patients.
Risk factors for the onset of nephrotoxicity
Risk factors for the onset of nephrotoxicity are listed in Table 2 . In the multivariate analysis, only three variables (daily dose by actual body weight, concurrent use of vancomycin and contrast media) were found to be independently associated with the onset of nephrotoxicity, after adjusting for underlying confounders.
Model validation
By conditioning the best-fit model using patient-specific risk factors, the patients were stratified into two cohorts based on the predicted hazards. Patients with above the median predicted hazards were classified as high-risk patients and patients with below the median predicted hazards were categorized as low-risk patients. A comparison of the cohorts stratified by the predicted hazards is shown in Table 3 . The time to nephrotoxicity between the two stratified cohorts is as shown in Figure 1 . As anticipated, the time to nephrotoxicity was significantly earlier in the high-risk group (P ¼ 0.003).
Discussion
With a rising prevalence of multidrug resistance in Gram-negative bacteria, the polymyxins are going to be increasingly used as the treatment of last resort. Over the past decade, several pivotal studies have provided critical information on the optimal dosing regimen of polymyxin B. Since the area under the concentration -time curve (AUC)/MIC best describes the bactericidal activity of polymyxin B, using higher doses should be associated with better outcomes (when susceptibility remains unchanged). 16 Consistent with our expectation, Elias et al. 14 reported that a daily dosage of ≥2 million IU of polymyxin B (equivalent to the activity of 200 mg of purified polymyxin B1 component) was associated with lower in-hospital mortality. However, a daily polymyxin B dose of ≥2 million IU was found to significantly increase the probability of AKI. 10, 14 A study by Kubin et al. 13 also reported that therapy was discontinued in 14% of patients given polymyxin B due to nephrotoxicity. These findings suggest that nephrotoxicity is a dose-limiting adverse effect of polymyxin B.
The overall prevalence rate of nephrotoxicity in our study was 45.8% (88/192), with the majority of the patients qualifying for the risk category (n ¼ 37), followed by the failure category (n ¼ 28). The rate of nephrotoxicity associated with polymyxin B Nephrotoxicity onset with polymyxin B
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JAC assessed using RIFLE criteria by four other studies ranged from 23.1% to 60%. 8, 9, 13, 17 The severity of nephrotoxicity was reported in two of these studies, where the majority of the patients qualified for the injury or failure categories. 8, 9 Although the observed rates of nephrotoxicity were high in these studies, kidney injury was reversible in the majority of the patients.
Understanding the temporal relationship for the development of kidney injury associated with polymyxin B therapy is vital to minimize nephrotoxicity and improve clinical outcomes. We have previously examined and reported the risk factors for nephrotoxicity associated with polymyxin B. 8 In the present study, we focused on the onset of nephrotoxicity. Currently there are limited data on the onset of nephrotoxicity. In an animal model, Abdelraouf et al. 12 reported that polymyxin B-induced nephrotoxicity manifested as acute tubular necrosis and extensive injury of the proximal tubules was observed. Polymyxin B dosing frequency had an impact on the onset of nephrotoxicity. The lesions were more severe and higher drug concentrations were achieved in the kidney in the six hourly dosing group. With the same daily dose, the once-daily dosing group experienced a more gradual onset of nephrotoxicity, which could be attributed to the lower kidney tissue drug concentrations.
12,18 Kubin et al. 13 showed that earlier onset and increased risk of nephrotoxicity was observed in patients with BMI ≥25 kg/m 2 including overweight, obese and volume-overloaded patients. Two other studies reported that onset of nephrotoxicity occurred earlier in patients who received colistin than in patients who were given polymyxin B. 8, 9 In our patients with normal baseline renal function, the median duration of polymyxin B treatment was 9.5 days (IQR ¼ 7 -14 days) and the median onset of nephrotoxicity (regardless of severity) was 9 days (IQR¼ 5 -16 days). These findings are consistent with several other studies that examined the onset of nephrotoxicity in patients who received polymyxin B. In a retrospective study by Kubin et al. 13 (n¼ 73), the median duration of polymyxin B therapy was 11 days and the median time to the first sign of AKI was 4 days (range 1 -14 days). In comparison, Akajagbor et al. 9 (n ¼ 67) reported a mean time to peak serum creatinine of 7.3 days with a mean treatment duration of 12.5 days. Similarly, Esaian et al. 17 (n ¼ 80) reported a mean time to peak serum creatinine of 9 days. Collectively, these findings suggested that kidney injury typically occurred after 1 week of therapy and the average time to peak serum creatinine was 7 -9 days.
Independent risk factors for the onset of polymyxin B-associated nephrotoxicity identified in our study included daily dose by actual body weight, concurrent use of vancomycin and contrast media. Taking one step further to validate the best-fit model derived, we stratified the patients by the predicted hazards and compared the time to nephrotoxicity between the two patient strata. Time to nephrotoxicity was significantly earlier in the highrisk group (P ¼ 0.003). The finding that concomitant vancomycin might play a role in augmenting the nephrotoxicity associated with polymyxin B was also suggested by two other studies. 10, 13 Additional independent predictors of polymyxin B-associated AKI described by other studies include age, the need for vasoactive drugs, duration of therapy and BMI ≥25 kg/m 2 . 8, 9, 13, 19, 20 There are several limitations to our study. We had a small sample size; therefore, we might not have been able to examine the contribution of all possible risk factors. Also, since it was a multicentre study, there could be variation among the participating hospitals in patient population, the standard of care, specific polymyxin B products used, dosing regimens and infusion time utilized. We did not include patients with underlying renal insufficiency; therefore, the results should not be extrapolated to these patients. In addition, we did not evaluate illness acuteness comprehensively (other than tracking patient stay in ICUs and the use of vasoactive agents). Finally, we did not evaluate fluid balance status and urinary output of the patients, which might have an effect on the development of kidney injury.
In summary, our study identified risk factors for the onset of nephrotoxicity associated with polymyxin B therapy. In conjunction with susceptibility and other pharmacokinetic/pharmacodynamic data, our results can be used to optimize polymyxin B treatment for MDR Gram-negative infections. Further investigations are ongoing to minimize nephrotoxicity associated with polymyxin B.
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